首頁 > 市場調查報告書 > 醫療設備

眼科設備

市場調查報告書

商品編碼

1733384

全球眼科藥物和設備市場規模（按產品類型、應用、最終用戶、區域範圍和預測）

Global Ophthalmology Drugs And Devices Market Size By Product Type (Anti-inflammatory, Anti-glaucoma), By Application (Dry Eye, Eye Allergy), By End-User (Hospitals, Medical Clinics), By Geographic Scope And Forecast

出版日期: 2025年05月13日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

眼科藥物及器械市場規模及預測

2024 年眼科藥物和設備市場規模價值為 570.2 億美元，預計到 2032 年將達到 881.8 億美元，2024 年至 2032 年的複合年成長率為 5.60%。

眼部疾病和病症的盛行率不斷上升、人們對眼部疾病的健康意識不斷增強、強大的分子管道的存在以及眼科藥物和設備的日益普及，極大地推動了全球眼科藥物和設備市場的成長。本報告對全球眼科藥品和設備市場進行了全面的評估。它對關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

定義全球眼科藥物和設備市場

眼科是專注於眼科疾病的診斷和治療的醫學領域。眼科設備用於各種手術，包括白內障手術、青光眼手術和屈光矯正手術。眼科治療用於治療多種眼科疾病，包括感染疾病、青光眼和白內障。由於老年族群中黃斑部病變、老花眼和糖尿病視網膜病變等眼部疾病的發生率和盛行率不斷上升，全球眼科藥品和設備市場正經歷顯著成長。隨著先進的眼科設備的出現，越來越多的人選擇透過眼科手術來治療眼部疾病。

全球眼科藥物和設備市場概況

由於老年族群對治療黃斑部病變、老花眼、糖尿病視網膜病變等各種眼部疾病的微創手術的需求不斷增加，預計未來幾年全球眼科藥物和設備市場將出現顯著成長。眼科疾病和障礙的發病率和盛行率不斷增加、人們對眼科疾病和障礙的健康意識不斷增強、強大的分子管道的存在以及眼科治療和設備在某些眼部異常和眼部缺陷的治療和診斷中的應用日益增多，極大地推動了全球眼科治療和設備市場的成長。

此外，眼科藥物和設備領域的技術進步以及對開發新型眼科藥物的研發活動的投資增加也在推動市場成長。此外，全球老齡人口的成長、高血糖導致的眼部疾病的增加、醫療保健領域的成長以及政府以資金和津貼形式為診斷設備和治療程序提供的舉措和支持不斷增加，也推動了眼科藥物和設備市場的成長。

此外，預計在預測期內，患有眼部疾病的患者數量不斷增加、產品開發和發布活動的活性化、對人工水晶體和超音波設備的巨大需求以及新興國家的成長潛力將為全球眼科藥物和設備市場的相關人員提供豐厚的成長機會。然而，治療程序成本高、多種藥物核准延遲、眼科藥物認知度低、熟練醫務人員短缺以及專利到期預計將在預測期內阻礙全球眼科藥物和設備市場的成長。此外，治療眼科疾病的風險對眼科藥品和設備市場的成長構成了挑戰。

Carl Zeiss AG
Novartis AG
Johnson And Johnson Services, Inc.
Allergan
Topcon Corporation
Nidek Co., Ltd.
HAAG-STREIT GROUP
Ziemer Ophthalmic Systems
Bausch And Lomb Incorporated, BIoTech
VisionCare, Inc.
Akorn
Incorporated
Bayer AG
Acucela Inc.
Regeneron Pharmaceuticals, Inc
Nicox
Santen Pharmaceutical Co., Ltd
IRIDEX Corporation
Alcon Inc

第11章公司簡介附錄

相關報告

簡介目錄

Product Code: 69397

Ophthalmology Drugs And Devices Market Size And Forecast

Ophthalmology Drugs And Devices Market size was valued at USD 57.02 Billion in 2024 and is projected to reach USD 88.18 Billion by 2032, growing at a CAGR of 5.60% from 2024 to 2032.

The increasing prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices are driving the growth of the Global Ophthalmology Drugs And Devices Market significantly. The Global Ophthalmology Drugs And Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Ophthalmology Drugs And Devices Market Definition

Ophthalmology is a field of medical science that focuses on the diagnosis and treatment of eye disorders. Ophthalmic devices are used in a variety of procedures such as cataract surgery, glaucoma surgery, and refractive surgery. Ophthalmic drugs are used to treat a wide range of eye diseases, including infection, glaucoma, and cataract. The Global Ophthalmology Drugs And Devices Market is experiencing significant growth because of the rising incidence and prevalence of eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. With the advent of sophisticated ophthalmic devices, people are increasingly going to opt for ophthalmic surgeries to cure their eye-related disorders.

Global Ophthalmology Drugs And Devices Market Overview

The Global Ophthalmology Drugs And Devices Market is expected to experience remarkable growth in the upcoming years owing to the increasing demand for minimally invasive surgeries in the treatment of various eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. The increasing incidence and prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices in the treatment and diagnosis of certain ocular malformations and eye deficits are fueling the growth of Global Ophthalmology Drugs And Devices Market significantly.

Additionally, technological advancement in the field of Ophthalmology Drugs and Devices and increasing investment in R&D activities for the development of new ophthalmological drugs are also promoting market growth. Furthermore, the rise in the geriatric population across the globe, increasing ophthalmic disorders due to high blood sugar, growth in the healthcare sector, and increasing government initiatives and support in the form of funds and grants for diagnostic equipment and treatment procedures, also boost the growth of the Ophthalmology Drugs And Devices Market.

Moreover, an increase in the patient population of eye-related disorders, increasing product development and launch activities, huge demand for intraocular lenses and phacoemulsification devices, and growth potential in developing nations are expected to provide profitable growth opportunities to the market players in the Global Ophthalmology Drugs And Devices Market during the forecast period. However, high cost associated with the treatment procedures, drug approval delays wherein multiple drugs are in the pipeline, low awareness of ophthalmic drugs, lack of skilled healthcare professionals, and patent expiry is expected to hinder the growth of the Global Ophthalmology Drugs And Devices Market over the forecast period. In addition, risks associated with ocular disease treatment are posing challenges to the growth of the Ophthalmology Drugs And Devices Market.

Global Ophthalmology Drugs And Devices Market Segmentation Analysis

The Global Ophthalmology Drugs And Devices Market is Segmented on the basis of Product Type, Application, End-User, and Geography.

Ophthalmology Drugs And Devices Market, By Product Type

Anti-allergy
Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
Anti-inflammatory
Anti-glaucoma
Diagnostic and Monitoring Devices
Surgical Devices
Vision Care
Others

Based on Product Type, the market is bifurcated into Anti-allergy, Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents, Anti-inflammatory, Anti-glaucoma, Diagnostic and Monitoring Devices, Surgical Devices, Vision Care, and Others. The anti-inflammatory segment accounts for the highest revenue share of the Global market in 2020 and is expected to dominate the market over the forecast period owing to an increase in the prevalence of allergic conjunctivitis and hypersensitivity reactions, as well as an increase in demand for anti-inflammatory drugs in a wide range of conditions such as uveitis, cystoid macular edema, and scleritis. These factors are driving the growth of this segment.

Ophthalmology Drugs And Devices Market, By Application

Dry Eye
Eye Allergy
Glaucoma
Cataract
Eye Infection
Retinal Disorders
Uveitis
Others

Based on Application, the market is bifurcated into Dry Eye, Eye Allergy, Glaucoma, Cataract, Eye Infection, Retinal Disorders, Uveitis, and Others. The retinal disorders segment is expected to hold the largest revenue share of the global market during the forecast period owing to the rise in the geriatric population, increase in the prevalence of macular degeneration, and an increase in the sale of ophthalmic drugs for the treatment of retinal disorders. However, the glaucoma segment is expected to grow significantly during the forecast period due to an increase in glaucoma prevalence, a rising need for ophthalmic drugs, and an increase in glaucoma prevention and treatment awareness.

Ophthalmology Drugs And Devices Market, By End-User

Hospitals
Medical Clinics
Diagnostic Centers
Others

Based on End-User, the market is bifurcated into Hospitals, Medical Clinics, Diagnostic Centers, and Others. The hospitals segment is expected to grow at the highest CAGR during the forecast period owing to the increasing number of patients suffering from various eye-related disorders, and rising awareness about these disorders. Additionally, the availability of various diagnostics and treatment facilities, higher purchasing power, and the presence of highly skilled eye care professionals are driving the growth of the global market in the hospitals segment.

Ophthalmology Drugs And Devices Market, By Geography

North America
Europe
Asia Pacific
Rest of the World
On the basis of Regional Analysis, The Global Ophthalmology Drugs And Devices Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in the Global Ophthalmology Drugs And Devices Market in 2020 and is expected to retain its dominance throughout the forecast period. The revenue growth in the North American market is mainly attributed to the increased investment in R&D activities for the development of technologically advanced medical devices and innovative drugs for the treatment of various eye-related disorders.
Additionally, the increasing geriatric population, rising incidence and prevalence of various eye-related disorders, rising healthcare sectors, presence of skilled eye care professionals, and wide availability of technologically advanced ophthalmology devices are the major factors that boost the Ophthalmology Drugs And Devices Market growth across the region. The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to the increasing focus on the development of healthcare infrastructure and the rising prevalence of various eye-related disorders such as glaucoma and cataract in developing nations such as China, and India in this region.

Key Players

The "Global Ophthalmology Drugs And Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Carl Zeiss AG, Novartis AG, Johnson And Johnson Services, Inc., Allergan, Topcon Corporation, Nidek Co., Ltd., HAAG-STREIT GROUP, Ziemer Ophthalmic Systems, Bausch And Lomb Incorporated, Biotech, VisionCare, Inc., Akorn, Incorporated, Bayer AG, Acucela Inc., Regeneron Pharmaceuticals, Inc, Nicox, Santen Pharmaceutical Co., Ltd. and IRIDEX Corporation, Alcon Inc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

In August 2020, Topcon Corporation purchased the Henson line of perimetry products, including the Henson 9000 and 7000, from the United Kingdom-based Elektron Eye Technology (EET) of Cambridge.
In January 2020, iCare's IC200 tonometer device was approved by the US FDA.
In March 2019, Alcon Inc. acquired Power Vision Inc., a privately held medical device development company based in the United States that specializes in fluid-based intraocular lens implants.
In August 2018, CEQUA, developed by Sun Pharmaceutical Industries Ltd., had been approved by the US FDA for the treatment of dry eye diseases.
In July 2018, Amring Pharmaceuticals, Inc. introduced Biolon ophthalmic viscosurgical devices for cataract surgeons in the United States.

1 INTRODUCTION OF GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Anti-allergy
5.3 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
5.4 Anti-inflammatory
5.5 Anti-glaucoma
5.6 Diagnostic and Monitoring Devices
5.7 Surgical Devices
5.8 Vision Care
5.9 Others

6 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY APPLICATION

6.1 Overview
6.2 Dry Eye
6.3 Eye Allergy
6.4 Glaucoma
6.5 Cataract
6.6 Eye Infection
6.7 Retinal Disorders
6.8 Uveitis
6.9 Others

7 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY END-USER

7.1 Overview
7.2 Hospitals
7.3 Medical Clinics
7.4 Diagnostic Centers
7.5 Others

8 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Middle East and Africa
- 8.5.2 Latin America

9 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Carl Zeiss AG
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Novartis AG
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Johnson And Johnson Services, Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Allergan
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Topcon Corporation
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Nidek Co., Ltd.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 HAAG-STREIT GROUP
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Ziemer Ophthalmic Systems
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bausch And Lomb Incorporated, Biotech
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
9.10 VisionCare, Inc.
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments
9.11 Akorn
- 9.11.1 Overview
- 9.11.2 Financial Performance
- 9.11.3 Product Outlook
- 9.11.4 Key Developments
9.12 Incorporated
- 9.12.1 Overview
- 9.12.2 Financial Performance
- 9.12.3 Product Outlook
- 9.12.4 Key Developments
9.13 Bayer AG
- 9.13.1 Overview
- 9.13.2 Financial Performance
- 9.13.3 Product Outlook
- 9.13.4 Key Developments
9.14 Acucela Inc.
- 9.14.1 Overview
- 9.14.2 Financial Performance
- 9.14.3 Product Outlook
- 9.14.4 Key Developments
9.15 Regeneron Pharmaceuticals, Inc
- 9.15.1 Overview
- 9.15.2 Financial Performance
- 9.15.3 Product Outlook
- 9.15.4 Key Developments
9.16 Nicox
- 9.16.1 Overview
- 9.16.2 Financial Performance
- 9.16.3 Product Outlook
- 9.16.4 Key Developments
9.17 Santen Pharmaceutical Co., Ltd
- 9.17.1 Overview
- 9.17.2 Financial Performance
- 9.17.3 Product Outlook
- 9.17.4 Key Developments
9.18 IRIDEX Corporation
- 9.18.1 Overview
- 9.18.2 Financial Performance
- 9.18.3 Product Outlook
- 9.18.4 Key Developments
9.19 Alcon Inc
- 9.19.1 Overview
- 9.19.2 Financial Performance
- 9.19.3 Product Outlook
- 9.19.4 Key Developments